Retargeting of killer cells with bispecific antibodies greatly enchances MUC1 specific cytotoxicity

T. Kudo, Yu Katayose, M. Shinoda, K. Imai

Research output: Contribution to journalArticlepeer-review

Abstract

For the purpose of establishing a new effective adoptive immunotherapy, we synthesized two bispecific antibodies (BsAbs), MUC1 x CD3 BsAb constructed with MUSE11 (anti MUC1) and OKT3; and MUC1 x CD28 BsAB constructed with MUSE11 and 15E8 (anti CD28) antibodies. These two BsAbs reacted well with tumor (TFK 1) and LAK cells. When 2 x 107 LAK cells sensitized with both kinds of BsAbs were administered intravenously to TFK 1 grafted SCID mice (tumor size 5 mm), inhibition of tumor growth was clearly observed. In order to obtain effective vaccine cells, we transfected MUC1 gene to EBV lymphoblastoid cells. The established vaccine cells induced highly active killer cells in the autologous MLTC. Thus, we suggest vaccine combined specific targeting therapy using the two kinds of BsAbs as potential therapy for control of MUC1 positive tumors.

Original languageEnglish
Pages (from-to)331-333
Number of pages3
JournalBiotherapy
Volume11
Issue number3
Publication statusPublished - 1997 Jan 1

Keywords

  • Bispecific antibody
  • LAK
  • MLTC
  • MUC1
  • SCID mouse

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Retargeting of killer cells with bispecific antibodies greatly enchances MUC1 specific cytotoxicity'. Together they form a unique fingerprint.

Cite this